iBio Inc.

News & Events

Press Releases

In The Media

1. iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

   GlobeNewswire SEP 5, 2025 7:30 AM EDT
   SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovato...
   Read Article

2. iBio Announces Closing of $50 Million Public Offering

   GlobeNewswire AUG 25, 2025 7:00 AM EDT
   Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised...
   Read Article

3. iBio Announces Pricing of $50 Million Public Offering

   GlobeNewswire AUG 19, 2025 8:01 AM EDT
   SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovato...
   Read Article

4. iBio Announces Proposed Public Offering

   GlobeNewswire AUG 18, 2025 4:01 PM EDT
   SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovato...
   Read Article

5. iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

   GlobeNewswire JUN 24, 2025 7:00 AM EDT
   Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mou...
   Read Article

6. iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

   GlobeNewswire JUN 23, 2025 4:15 PM EDT
   Review of promising Myostatin and Activin E antibody data iBio to announce 3 rd ...
   Read Article

7. iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

   GlobeNewswire JUN 16, 2025 7:00 AM EDT
   iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody ...
   Read Article

8. iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

   GlobeNewswire MAY 5, 2025 8:00 AM EDT
   Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fa...
   Read Article

9. iBio Reports Fiscal Third Quarter 2025 Financial Results

   GlobeNewswire MAY 2, 2025 8:00 AM EDT
   SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial re...
   Read Article

10. iBio Raises $6.2 Million Through Warrant Inducement Transaction

    GlobeNewswire APR 29, 2025 1:43 PM EDT
    SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or ...
    Read Article